Receipt of Good Manufacturing Practices (GMP) Compliance Certificate by Caplin One Labs Limited (COL), a subsidiary Company, from INVIMA

September 01, 2026 BSE Limited National Stock Exchange of India Ltd., Department of Corporate Relationship Department of Corporate Services 1st Floor, New Trade Ring, Rotunda Building Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers C-1, Block G,Bandra Kurla Complex, Dalal Street, Mumbai- 400001 Bandra (E),Mumbai – 400 051 Scrip Code: 524742 S c r i p C o d e : C A P L I P O I N T . Dear Sir/Madam, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Receipt of Good Manufacturing Practices (GMP) Compliance Certification by Caplin One Labs Limited (COL), a subsidiary company, from INVIMA (Instituto Nacional de Vigilancia de Medicamentosy Alimentos), Colombia This is to inform the Exchanges that the manufacturing unit of COL, a subsidiary of the Company, located at Survey No. 499/-, 88/-, 500/-, 89/1, Plot No. G-44, G-45 & G-46, Block A and Block B, SIDCO Industrial Estate, Kakkalur, Tiruvallur District, Tamil Nadu, India, has received confirmation of compliance with Good Manufacturing Practices (GMP) from the National Institute for the Surveillance of Food and Drugs (INVIMA), the regulatory authority designated by the Ministry of Health and Social Protection of the Republic of Colombia. INVIMA had concluded that COL complies with the GMP requirements for the manufacture of the following oncology drug products: Category Dosage Form(s) Sterile Lyophilized powder for injection (in vials) Non-Sterile Tablets (Coated and Uncoated), Hard capsules The formal certificate from INVIMA is expected to be received in due course. This is for your kind information and records. Kindly acknowledge the receipt. Thanking You, Sincerely yours, For Caplin Point Laboratories Limited Venkatram G General Counsel & Company Secretary Membership No A23989